{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1360002219002500352.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1186/s13024-016-0072-9"}},{"identifier":{"@type":"URI","@value":"http://link.springer.com/content/pdf/10.1186/s13024-016-0072-9"}},{"identifier":{"@type":"PMID","@value":"26782965"}},{"identifier":{"@type":"HANDLE","@value":"10576/4952"}}],"resourceType":"学術雑誌論文(journal article)","dc:title":[{"@value":"Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson’s disease"}],"description":[{"notation":[{"@value":"Despite decades of intensive research, to date, there is no accepted diagnosis for Parkinson's disease (PD) based on biochemical analysis of blood or CSF. However, neurodegeneration in the brains of PD patients begins several years before the manifestation of the clinical symptoms, pointing to serious flaw/limitations in this approach.To explore the potential use of alpha-synuclein (α-syn) species as candidate biomarkers for PD, we generated specific antibodies directed against wide array of α-syn species, namely total-, oligomeric- and phosphorylated-Ser129-α-syn (t-, o- and p-S129-α-syn). Next we sought to employ our antibodies to develop highly specific ELISA assays to quantify α-syn species in biological samples. Finally we verified the usefulness of our assays in CSF samples from 46 PD patients and 48 age-matched healthy controls. We also assessed the discriminating power of combining multiple CSF α-syn species with classical Alzheimer's disease biomarkers. The combination of CSF o-/t-α-syn, p-S129-α-syn and p-tau provided the best fitting predictive model for discriminating PD patients from controls. Moreover, CSF o-α-syn levels correlated significantly with the severity of PD motor symptoms (r = -0.37).Our new ELISA assays can serve as research tools to address the unmet need for reliable CSF biomarkers for PD and related disorders."}]}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1380003447287204481","@type":"Researcher","foaf:name":[{"@value":"Nour K. Majbour"}]},{"@id":"https://cir.nii.ac.jp/crid/1380003447287204616","@type":"Researcher","foaf:name":[{"@value":"Nishant N. Vaikath"}]},{"@id":"https://cir.nii.ac.jp/crid/1380003447287204609","@type":"Researcher","foaf:name":[{"@value":"Karin D. van Dijk"}]},{"@id":"https://cir.nii.ac.jp/crid/1380003447287204608","@type":"Researcher","foaf:name":[{"@value":"Mustafa T. Ardah"}]},{"@id":"https://cir.nii.ac.jp/crid/1380003447287204613","@type":"Researcher","foaf:name":[{"@value":"Shiji Varghese"}]},{"@id":"https://cir.nii.ac.jp/crid/1380003447287204614","@type":"Researcher","foaf:name":[{"@value":"Louise B. Vesterager"}]},{"@id":"https://cir.nii.ac.jp/crid/1380003447287204480","@type":"Researcher","foaf:name":[{"@value":"Liliana P. Montezinho"}]},{"@id":"https://cir.nii.ac.jp/crid/1380003447287204617","@type":"Researcher","foaf:name":[{"@value":"Stephen Poole"}]},{"@id":"https://cir.nii.ac.jp/crid/1380003447287204610","@type":"Researcher","foaf:name":[{"@value":"Bared Safieh-Garabedian"}]},{"@id":"https://cir.nii.ac.jp/crid/1420001326224702592","@type":"Researcher","personIdentifier":[{"@type":"KAKEN_RESEARCHERS","@value":"80242692"},{"@type":"NRID","@value":"1000080242692"},{"@type":"NRID","@value":"9000238225627"},{"@type":"NRID","@value":"9000004245893"},{"@type":"NRID","@value":"9000258060830"},{"@type":"NRID","@value":"9000018881365"},{"@type":"NRID","@value":"9000000728621"},{"@type":"NRID","@value":"9000001056159"},{"@type":"NRID","@value":"9000347091924"},{"@type":"NRID","@value":"9000258213864"},{"@type":"NRID","@value":"9000317135718"},{"@type":"NRID","@value":"9000356654212"},{"@type":"NRID","@value":"9000397805321"},{"@type":"NRID","@value":"9000252780631"},{"@type":"NRID","@value":"9000018800727"},{"@type":"NRID","@value":"9000331431948"},{"@type":"NRID","@value":"9000283542120"},{"@type":"NRID","@value":"9000411514784"},{"@type":"NRID","@value":"9000018685491"},{"@type":"NRID","@value":"9000327104921"},{"@type":"NRID","@value":"9000258058220"},{"@type":"NRID","@value":"9000024944770"},{"@type":"NRID","@value":"9000341531268"},{"@type":"NRID","@value":"9000022137660"},{"@type":"NRID","@value":"9000310333375"},{"@type":"NRID","@value":"9000019050817"},{"@type":"NRID","@value":"9000411396808"},{"@type":"NRID","@value":"9000020169173"},{"@type":"NRID","@value":"9000404787854"},{"@type":"NRID","@value":"9000363898048"},{"@type":"NRID","@value":"9000258059891"},{"@type":"NRID","@value":"9000018927294"},{"@type":"NRID","@value":"9000293504560"},{"@type":"RESEARCHMAP","@value":"https://researchmap.jp/read0010394"}],"foaf:name":[{"@value":"Takahiko Tokuda"}]},{"@id":"https://cir.nii.ac.jp/crid/1380003447287204615","@type":"Researcher","foaf:name":[{"@value":"Charlotte E. Teunissen"}]},{"@id":"https://cir.nii.ac.jp/crid/1380003447287204612","@type":"Researcher","foaf:name":[{"@value":"Henk W. Berendse"}]},{"@id":"https://cir.nii.ac.jp/crid/1380003447287204482","@type":"Researcher","foaf:name":[{"@value":"Wilma D. J. van de Berg"}]},{"@id":"https://cir.nii.ac.jp/crid/1380003447287204483","@type":"Researcher","foaf:name":[{"@value":"Omar M. A. El-Agnaf"}]}],"publication":{"publicationIdentifier":[{"@type":"EISSN","@value":"17501326"}],"prism:publicationName":[{"@value":"Molecular Neurodegeneration"}],"dc:publisher":[{"@value":"Springer Science and Business Media LLC"}],"prism:publicationDate":"2016-01-19","prism:volume":"11","prism:number":"1","prism:startingPage":"7"},"reviewed":"false","dcterms:accessRights":"http://purl.org/coar/access_right/c_abf2","url":[{"@id":"http://link.springer.com/content/pdf/10.1186/s13024-016-0072-9"}],"createdAt":"2016-01-19","modifiedAt":"2024-06-13","foaf:topic":[{"@id":"https://cir.nii.ac.jp/all?q=Male","dc:title":"Male"},{"@id":"https://cir.nii.ac.jp/all?q=Clinical%20Neurology","dc:title":"Clinical Neurology"},{"@id":"https://cir.nii.ac.jp/all?q=610","dc:title":"610"},{"@id":"https://cir.nii.ac.jp/all?q=tau%20Proteins","dc:title":"tau Proteins"},{"@id":"https://cir.nii.ac.jp/all?q=Cellular%20and%20Molecular%20Neuroscience","dc:title":"Cellular and Molecular Neuroscience"},{"@id":"https://cir.nii.ac.jp/all?q=Cerebrospinal%20fluid%20biomarkers","dc:title":"Cerebrospinal fluid biomarkers"},{"@id":"https://cir.nii.ac.jp/all?q=Alzheimer%20Disease","dc:title":"Alzheimer Disease"},{"@id":"https://cir.nii.ac.jp/all?q=Alpha%20synuclein","dc:title":"Alpha synuclein"},{"@id":"https://cir.nii.ac.jp/all?q=Animals","dc:title":"Animals"},{"@id":"https://cir.nii.ac.jp/all?q=Humans","dc:title":"Humans"},{"@id":"https://cir.nii.ac.jp/all?q=Phosphorylation","dc:title":"Phosphorylation"},{"@id":"https://cir.nii.ac.jp/all?q=Molecular%20Biology","dc:title":"Molecular Biology"},{"@id":"https://cir.nii.ac.jp/all?q=Aged","dc:title":"Aged"},{"@id":"https://cir.nii.ac.jp/all?q=Amyloid%20beta-Peptides","dc:title":"Amyloid beta-Peptides"},{"@id":"https://cir.nii.ac.jp/all?q=Brain","dc:title":"Brain"},{"@id":"https://cir.nii.ac.jp/all?q=Parkinson%20Disease","dc:title":"Parkinson Disease"},{"@id":"https://cir.nii.ac.jp/all?q=Middle%20Aged","dc:title":"Middle Aged"},{"@id":"https://cir.nii.ac.jp/all?q=Parkinson%E2%80%99s%20disease","dc:title":"Parkinson’s disease"},{"@id":"https://cir.nii.ac.jp/all?q=alpha-Synuclein","dc:title":"alpha-Synuclein"},{"@id":"https://cir.nii.ac.jp/all?q=Female","dc:title":"Female"},{"@id":"https://cir.nii.ac.jp/all?q=Protein%20Multimerization","dc:title":"Protein Multimerization"},{"@id":"https://cir.nii.ac.jp/all?q=Biomarkers","dc:title":"Biomarkers"},{"@id":"https://cir.nii.ac.jp/all?q=Research%20Article","dc:title":"Research Article"}],"project":[{"@id":"https://cir.nii.ac.jp/crid/1040282256827537536","@type":"Project","projectIdentifier":[{"@type":"KAKEN","@value":"15K09322"},{"@type":"JGN","@value":"JP15K09322"},{"@type":"URI","@value":"https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-15K09322/"}],"notation":[{"@language":"ja","@value":"パーキンソン病の神経障害性α-シヌクレインオリゴマーの同定と分子標的治療への応用"},{"@language":"en","@value":"Identification of neurotoxic alpha-synuclein oligomers in Parkinson's disease and its application to molecular targeted therapy"}]}],"relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1050299693922654208","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Ultrasonication-based rapid amplification of α-synuclein aggregates in cerebrospinal fluid"},{"@value":"Ultrasonication-based rapid amplification of alpha-synuclein aggregates in cerebrospinal fluid"},{"@value":"Ultrasonication-based rapid amplification of a-synuclein aggregates in cerebrospinal fluid"}]},{"@id":"https://cir.nii.ac.jp/crid/1050856995321744768","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Diagnosis of Parkinson's disease by investigating the inhibitory effect of serum components on P450 inhibition assay"}]},{"@id":"https://cir.nii.ac.jp/crid/1360011146127526400","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Cerebrospinal fluid lysosomal enzymes and alpha‐synuclein in Parkinson's disease"}]},{"@id":"https://cir.nii.ac.jp/crid/1360285705198932736","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Longitudinal changes in CSF alpha‐synuclein species reflect Parkinson's disease progression"}]},{"@id":"https://cir.nii.ac.jp/crid/1360292618629266560","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Stage‐dependent nigral neuronal loss in incidental Lewy body and Parkinson's disease"}]},{"@id":"https://cir.nii.ac.jp/crid/1360292618930716544","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"CAMDEX: A Standardised Instrument for the Diagnosis of Mental Disorder in the Elderly with Special Reference to the Early Detection of Dementia"}]},{"@id":"https://cir.nii.ac.jp/crid/1360292619382215936","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Phosphorylation of Ser-129 Is the Dominant Pathological Modification of α-Synuclein in Familial and Sporadic Lewy Body Disease"}]},{"@id":"https://cir.nii.ac.jp/crid/1360292619962518016","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Parkinson's disease: clinical features and diagnosis"}]},{"@id":"https://cir.nii.ac.jp/crid/1360292620005749888","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"α-Synuclein aggregation in neurodegenerative diseases and its inhibition as a potential therapeutic strategy"}]},{"@id":"https://cir.nii.ac.jp/crid/1360292620255588736","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Structure activity relationship of phenolic acid inhibitors of α-synuclein fibril formation and toxicity"}]},{"@id":"https://cir.nii.ac.jp/crid/1360292620595324800","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"CSF biomarkers and clinical progression of Parkinson disease"}]},{"@id":"https://cir.nii.ac.jp/crid/1360306906091676416","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Biofluid Markers and Tissue Biopsies Analyses for the Prodromal and Earliest Phase of Parkinson’s Disease"}]},{"@id":"https://cir.nii.ac.jp/crid/1360565166041185152","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Generation and characterization of novel conformation-specific monoclonal antibodies for α-synuclein pathology"}]},{"@id":"https://cir.nii.ac.jp/crid/1360568471826323328","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Correlated levels of cerebrospinal fluid pathogenic proteins in drug-naïve Parkinson’s disease"}]},{"@id":"https://cir.nii.ac.jp/crid/1360574093579715456","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Baicalein Inhibits Formation of α‐Synuclein Oligomers within Living Cells and Prevents Aβ Peptide Fibrillation and Oligomerisation"}]},{"@id":"https://cir.nii.ac.jp/crid/1360574094072461696","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"The Formation of Highly Soluble Oligomers of α-Synuclein Is Regulated by Fatty Acids and Enhanced in Parkinson's Disease"}]},{"@id":"https://cir.nii.ac.jp/crid/1360574094737608448","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Development and application of radioimmunoassays for interleukin-1α and interleukin-1β"}]},{"@id":"https://cir.nii.ac.jp/crid/1360574096237841664","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Inhibition of fibril formation and toxicity of a fragment of α-synuclein by an N-methylated peptide analogue"}]},{"@id":"https://cir.nii.ac.jp/crid/1360576118680948096","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"It Is Time to Study Overlapping Molecular and Circuit Pathophysiologies in Alzheimer’s and Lewy Body Disease Spectra"}]},{"@id":"https://cir.nii.ac.jp/crid/1360848658470314112","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Increased levels of CSF total but not oligomeric or phosphorylated forms of alpha-synuclein in patients diagnosed with probable Alzheimer’s disease"}]},{"@id":"https://cir.nii.ac.jp/crid/1360855570244390016","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Copper‐mediated formation of hydrogen peroxide from the amylin peptide: A novel mechanism for degeneration of islet cells in type‐2 diabetes mellitus?"}]},{"@id":"https://cir.nii.ac.jp/crid/1360855571286087040","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Alpha-synuclein and tau: teammates in neurodegeneration?"}]},{"@id":"https://cir.nii.ac.jp/crid/1360855571319267712","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"RETRACTED: Accumulation of oligomer-prone α-synuclein exacerbates synaptic and neuronal degeneration\n                    <i>in vivo</i>"}]},{"@id":"https://cir.nii.ac.jp/crid/1360863723828109312","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Conformations of β‐Amyloid in Solution"}]},{"@id":"https://cir.nii.ac.jp/crid/1361137046110101504","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases."}]},{"@id":"https://cir.nii.ac.jp/crid/1361418518790678912","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Cerebrospinal Fluid α-Synuclein Predicts Cognitive Decline in Parkinson Disease Progression in the DATATOP Cohort"}]},{"@id":"https://cir.nii.ac.jp/crid/1361418519410559616","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Elevated Levels of α-Synuclein Oligomer in the Cerebrospinal Fluid of Drug-Naïve Patients with Parkinson's Disease"}]},{"@id":"https://cir.nii.ac.jp/crid/1361699993483707776","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Diagnosis and the premotor phase of Parkinson disease"}]},{"@id":"https://cir.nii.ac.jp/crid/1361699993531102208","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Detection of oligomeric forms of α‐synuclein protein in human plasma as a potential biomarker for Parkinson's disease"}]},{"@id":"https://cir.nii.ac.jp/crid/1361699994388988800","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Assay of Pyrogens by Interleukin-6 Release from Monocytic Cell Lines"}]},{"@id":"https://cir.nii.ac.jp/crid/1361699995870584320","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"CSF Biomarkers for Alzheimer's Disease Diagnosis"}]},{"@id":"https://cir.nii.ac.jp/crid/1361981468524034688","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Effect of the Disulfide Bridge and the C-Terminal Extension on the Oligomerization of the Amyloid Peptide ABri Implicated in Familial British Dementia"}]},{"@id":"https://cir.nii.ac.jp/crid/1361981470502893184","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Elevated levels of cerebrospinal fluid α-synuclein oligomers in healthy asymptomatic LRRK2 mutation carriers"}]},{"@id":"https://cir.nii.ac.jp/crid/1361981470834094976","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Detection of elevated levels of α-synuclein oligomers in CSF from patients with Parkinson disease"}]},{"@id":"https://cir.nii.ac.jp/crid/1362262944094777600","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Differential role of CSF alpha-synuclein species, tau, and Aβ42 in Parkinson's Disease"}]},{"@id":"https://cir.nii.ac.jp/crid/1362262944681440896","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Correlates of cerebrospinal fluid levels of oligomeric- and total-α-synuclein in premotor, motor and dementia stages of Parkinson’s disease"}]},{"@id":"https://cir.nii.ac.jp/crid/1362262945009934720","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study"}]},{"@id":"https://cir.nii.ac.jp/crid/1362262946311577600","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Variable expression of Parkinson's disease"}]},{"@id":"https://cir.nii.ac.jp/crid/1362825894793675520","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"α-Synuclein in Lewy bodies"}]},{"@id":"https://cir.nii.ac.jp/crid/1362825895012029440","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Red Blood Cells Are the Major Source of Alpha-Synuclein in Blood"}]},{"@id":"https://cir.nii.ac.jp/crid/1362825895355125760","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Ginsenoside Rb1 inhibits fibrillation and toxicity of alpha-synuclein and disaggregates preformed fibrils"}]},{"@id":"https://cir.nii.ac.jp/crid/1362825895806784384","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Lewy pathology is not the first sign of degeneration in vulnerable neurons in Parkinson disease"}]},{"@id":"https://cir.nii.ac.jp/crid/1363107369577923072","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Amyloid-β(1–42), Total Tau, and Phosphorylated Tau as Cerebrospinal Fluid Biomarkers for the Diagnosis of Alzheimer Disease"}]},{"@id":"https://cir.nii.ac.jp/crid/1363107369689491584","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Cerebrospinal fluid Tau/α‐synuclein ratio in Parkinson's disease and degenerative dementias"}]},{"@id":"https://cir.nii.ac.jp/crid/1363388844179866368","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Levels of cerebrospinal fluid α-synuclein oligomers are increased in Parkinson’s disease with dementia and dementia with Lewy bodies compared to Alzheimer’s disease"}]},{"@id":"https://cir.nii.ac.jp/crid/1363388844996902016","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Soluble oligomers for the diagnosis of neurodegenerative diseases"}]},{"@id":"https://cir.nii.ac.jp/crid/1363951794528631424","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Detection of elevated levels of soluble  -synuclein oligomers in post-mortem brain extracts from patients with dementia with Lewy bodies"}]},{"@id":"https://cir.nii.ac.jp/crid/1363951795478707712","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Interference from Heterophilic Antibodies in Amyloid-β Oligomer ELISAs"}]},{"@id":"https://cir.nii.ac.jp/crid/1363951795777826560","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Incidental Lewy Body Disease and Preclinical Parkinson Disease"}]},{"@id":"https://cir.nii.ac.jp/crid/1364233269964186752","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Decreased α-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson’s disease"}]},{"@id":"https://cir.nii.ac.jp/crid/1364233270820855680","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Reduced α‐synuclein levels in cerebrospinal fluid in <scp>P</scp>arkinson's disease are unrelated to clinical and imaging measures of disease severity"}]},{"@id":"https://cir.nii.ac.jp/crid/1364233271242134272","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Increased CSF α‐synuclein levels in Alzheimer's disease: Correlation with tau levels"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1186/s13024-016-0072-9"},{"@type":"KAKEN","@value":"PRODUCT-20198770"},{"@type":"OPENAIRE","@value":"doi_dedup___::fca5a10d1be8aa6936fcf8a865328b70"},{"@type":"CROSSREF","@value":"10.1002/mds.26754_references_DOI_9bzGooxTPubM8k1ylRbblkakbr"},{"@type":"CROSSREF","@value":"10.3233/jpd-240007_references_DOI_9bzGooxTPubM8k1ylRbblkakbr"},{"@type":"CROSSREF","@value":"10.1186/s12883-019-1346-y_references_DOI_9bzGooxTPubM8k1ylRbblkakbr"},{"@type":"CROSSREF","@value":"10.3389/fnsys.2021.777706_references_DOI_9bzGooxTPubM8k1ylRbblkakbr"},{"@type":"CROSSREF","@value":"10.1038/s41598-019-42399-0_references_DOI_9bzGooxTPubM8k1ylRbblkakbr"},{"@type":"CROSSREF","@value":"10.1038/srep40263_references_DOI_9bzGooxTPubM8k1ylRbblkakbr"},{"@type":"CROSSREF","@value":"10.1038/s41598-022-10528-x_references_DOI_9bzGooxTPubM8k1ylRbblkakbr"}]}